InvestorsHub Logo
Followers 4
Posts 702
Boards Moderated 0
Alias Born 05/19/2016

Re: Turner2017 post# 91125

Sunday, 02/12/2017 11:34:41 PM

Sunday, February 12, 2017 11:34:41 PM

Post# of 463872
According to Missling, there is enough cash in hand to fund everything we are planning for the next two years.

Avg cost of the current phas 2a trial per patient is $34000/year. If this average holds for phase 2/3 that means a total yearly cost of $10.2M.

That is easily within our current capabilities. Should hold off on the partnership till absolutely necessary.

IMO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News